Antitumor activity of scorpion venom-derived peptides: A meta-analysis of preclinical studies

Posted by
  Antitumor activity of scorpion venom-derived peptides: A meta-analysis of preclinical studies Abstract Despite advances in cancer therapeutics, there are still challenges in improving drug toxicity and selectivity. Peptides from various venous species have recently garnered attention for their biopharmaceutical potential, particularly in cancer. The present study aimed to conduct a meta-analysis of the antitumor activity of scorpion venom-derived peptides (SVDPs) previously reported in preclinical models. The bibliographic research included original and review articles written in English published from 2015 to 2026. Studies within the scope were retrieved from the EBSCO Discovery Service, PubMed, and WIPO databases. A total of 27 articles that met the inclusion and exclusion criteria were included in this research, and the collected data were synthesized through a meta-analysis. In the included in vitro and in vivo studies, the effect of SVDPs on breast/mammary gland, cervical,...

Nanobody-based recombinant antivenom for cobra, mamba and rinkhals bites

Posted by

 


Nanobody-based recombinant antivenom for cobra, mamba and rinkhals bites

Abstract

Each year, snakebite envenoming claims thousands of lives and causes severe injury to victims across sub-Saharan Africa, many of whom depend on antivenoms derived from animal plasma as their sole treatment option1. Traditional antivenoms are expensive, can cause adverse immunological reactions, offer limited efficacy against local tissue damage and are often ineffective against all medically relevant snake species2. There is thus an urgent unmet medical need for innovation in snakebite envenoming therapy. However, developing broad-spectrum treatments is highly challenging owing to the vast diversity of venomous snakes and the complex and variable composition of their venoms3. Here we addressed this challenge by immunizing an alpaca and a llama with the venoms of 18 different snakes, including mambas, cobras and a rinkhals, constructing phage display libraries, and identifying high-affinity broadly neutralizing nanobodies. We combined eight of these nanobodies into a defined oligoclonal mixture, resulting in an experimental polyvalent recombinant antivenom that was capable of neutralizing seven toxin families or subfamilies. This antivenom effectively prevented venom-induced lethality in vivo across 17 African elapid snake species and markedly reduced venom-induced dermonecrosis for all tested cytotoxic venoms. The recombinant antivenom performed better than a currently used plasma-derived antivenom and therefore shows considerable promise for comprehensive, continent-wide protection against snakebites by all medically relevant African elapids.

Ahmadi, S., Burlet, N. J., Kerwin, S., Cardoso, I. A., Marriott, A. E., Edge, R. J., Crittenden, E., L., M., Nguyen, G. T., Wouters, Y., Kalogeropoulos, K., Thumtecho, S., Ebersole, T. W., Dahl, C. H., U., E., Jansen, T., Boddum, K., Manousaki, E., Ward, A. B., . . . Laustsen, A. H. (2025). Nanobody-based recombinant antivenom for cobra, mamba and rinkhals bites. Nature, 1-10. https://doi.org/10.1038/s41586-025-09661-0